Have a personal or library account? Click to login
Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases Cover

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases

Open Access
|Mar 2024

Figures & Tables

FIGURE 1.

Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 2.

Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 3.

Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

FIGURE 4.

Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

Patient demographics and clinicopathological features

Age in years
  Median (range)68 (34–85)
Sexn (%)
  Male22 (73)
  Female8 (27)
Primary tumour
  Colon16 (53)
  Rectum14 (47)
ECOG performance status
  018 (60)
  19 (30)
  23 (10)
Liver metastases
  Unilobar17 (57)
  Bilobar13 (43)
  ≤ 4 lesions19 (63)
  > 4 lesions11 (37)
Previous chemotherapy
  Yes17 (57)
  No13 (43)

Univariate analysis – influence of probable prognostic factors on overall survival

Characteristicsn (%)OS95 % CIp-value
Age ≤ 65 years11 (37)15.28.5–21.80.284
Age > 65 years19 (63)21.64.7–38.4.
Colon16 (53)23.716.8–30.50.145
Rectum14 (47)14.16.8–21.4
ECOG 018 (60)19.811.3–28.40.805
ECOG 1 or 212 (40)17.410.0–29.7
Previous chemotherapy17 (57)17.411.0–23.70.472
No previous chemotherapy13 (43)21.63.8–39.4
Unilobar disease17 (57)23.57.4–39.60.106
Bilobar disease13 (43)15.21.9–28.4
≤ 4 liver lesions19 (63)23.515.5–31.50.002
> 4 liver lesions11 (37)10.80.3–21.3
CEA ≤ 5 µg/L before the first DEBIRI TACE5 (27)17.45.9–28.90.591
CEA > 5 µg/L before the first DEBIRI TACE22 (73)15.29.2–21.1
Increase of serum CEA after first DEBIRI TACE10 (33)14.17.3–20.90.037
Decrease of serum CEA after first DEBIRI TACE12 (40)24.77.0–42.4
CEA stayed the same1 (3)25.5
CA 19-9 ≤ 37 kU/L before first DEBIRI TACE16 (53)15.210.1–20.20.393
CA 19-9 > 37 kU/L before first DEBIRI TACE11 (47)17.40.5–34.2
Increase of serum CA 19-9 after first DEBIRI TACE11 (48)15.211.7–18.70.583
Decrease of serum CA 19-9 after first DEBIRI TACE10 (43)19.80.0–44.9
CA 19-9 stayed the same2 (9)7.4
DOI: https://doi.org/10.2478/raon-2024-0023 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 214 - 220
Submitted on: Dec 13, 2023
Accepted on: Mar 6, 2024
Published on: Mar 30, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Maja Sljivic, Masa Sever, Janja Ocvirk, Tanja Mesti, Erik Brecelj, Peter Popovic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.